跳至主要内容
临床试验/CTRI/2024/10/075754
CTRI/2024/10/075754尚未招募不适用

A RANDOMIZED CONTROLLED CLINICAL STUDY OF EFFICACY OF HARIDRA DHUPAN IN THAMAK SHWASA VEGAWASTHA WITH SPECIAL REFERENCE TO BRONCHIAL ASTHMA

Dr Pushpa1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年11月5日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
30
试验地点
1
主要终点
To determine the effect of Haridra Dhupan in improving lung function such as

研究概览

简要总结

Ayurvedic literature has vast references of formulations indicated for clinical conditions similar to asthma. Particularly on haridra, previously very few research work was done in tamak shwas-vegawastha Thus, the present clinical study has been planned so as to establish an effective management of the same through the use of dhupan i.e. external procedure which is more safer, easily available at home, easily administrable and cost effective for the patient. So, for that purpose, we have chosen Haridra Dhupan. Haridra (Curcuma longa) can be regarded as drug for management of many diseases its mean phytocomponent is curcumin which displayed various pharmacological activities including anti-inflammatory, anti bacterial, immunostimulant, cardiovascular protective but, no such research work was done on action haridra in tamak shwasa vegawastha as dhupan dravya.

研究设计

研究类型
Interventional
分配方式
Coin toss, Lottery, toss of dice, shuffling cards etc
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Patients diagnosed with tamak shawas vegawastha/Bronchial Asthma.

排除标准

  • Patients having acute exacerbation of asthma at the time of registration Patients having severe persistent asthma as per GINA classification Patients having tuberculosis pneumonia bronchiectasis and SPO2 5 80% Patient having history of any hypersensitivity to any of the ingredient/s of the trial drugs Patients having history of malignancy Hematemesis,on immunotherapy and having any other concomitant systemic illness which required immediate medical intervention Patients receiving Steroid/ Broncho dilator (orally/inhaled) in last 6 hours Pregnant and lactating mothers Patients having bronchial asthma more than 5 years.

结局指标

主要结局

To determine the effect of Haridra Dhupan in improving lung function such as

时间窗: 5-7 minutes

PEFR FEV1 FVC

时间窗: 5-7 minutes

To determine the effect of Haridra Dhupan in improving asthma symptoms and

时间窗: 5-7 minutes

reducing the severity of tamak swasa vegawastha

时间窗: 5-7 minutes

次要结局

  • To study the effect of Haridra Dhupan on nasal symptoms score(To determine the safety of Haridra Dhupan in patients of Tamak Shwasa)

研究者

发起方
Dr Pushpa
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr Pushpa

Government Ayurvedic College , Nanded Maharashtra

研究点 (1)

Loading locations...

相似试验